BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Starting soon · Phase 1/Phase 2
Conditions studied: Inflammatory Bowel Diseases (IBD)
In brief
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.
Key facts
- Study ID
- NCT07544160
- Run by
- iCell Gene Therapeutics
- People needed
- 18
- Starts
- 2026-04-07
- Expected to finish
- 2028-04-07
- Last updated by the study team
- 2026-04-22
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Zhongshan people's hospital — Zhongshan, Guangdong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.